Amir Iravani
@DrAIravani
Theranostics and Molecular Imaging, #prostatecancer, #NET, @FredHutch. @UW
Great results and congratulations to everyone involved! First randomized trial of PSMA theranostics and unlike industry-sponsored trials against an active arm. @DrMHofman @drlouiseemmett @PeterMacCC @ANZUPtrials @pros_tic @WUSTLmed @MIRimaging
Continuing Education: Approaches to imaging immune activation using PET. ow.ly/vloI50VSPSh #PETscan #NuclearMedicine #MolecularImaging @DrAIravani @TheNUCguy
#PET is a critical tool for noninvasive imaging of immune activation and #immunotherapy: Approaches to Imaging Immune Activation Using PET jnm.snmjournals.org/content/66/6/8… Thanks to co-authors! @SNM_MI @fredhutch @UWMedicine @UWRadiology
Packed house at the first Theranostics Symposium by the University of Wisconsin Initiative for Theranostics and Particle Therapy.
Very pleased to see #NucMed perspective is included in a panel discussion on the patient-centerd management of high-risk #PSMA PET N1 disease at @ASCO 25, Drs Curtiland Deville (RadOnc), Alberto Birganti(SurgOnc), Alicia Morgan(MedOnc) and David Matheson(Patient ad) @SNM_MI
#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy @ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3…
Congrats @ANZUPtrials #ENZAp study oral presentation by @drlouiseemmett at #ASCSO25. @MovemberAUS @CancerAustralia @AstellasEurope #ARTnet @StVincentClinic @RoyMorganAus @Novartis @mimsoftware @GenesisCare @ANSTO @TrialsCentre @Prof_IanD
#ASCO25 #EVOLUTION #pcsm
Congrats to our @ANZUPTrials #EVOLUTIONtrial for on their oral presentation by @SandhuShahneen @ASCO25. This Phase 2 #ProstateCancer trial is supported by @PCFA and collaborators @TrialsCentre @bmsnews @Novartis Thanks Study Co-Chair @drlouiseemmett & @CancerAustralia @Prof_IanD
Congrats @ANZUPTrials #TheraP study presented #ASCO25 by Dr Aslı Munzur. Thanks to @PCFnews @bccancerfdn @TerryFoxCanada #CanadianCancerSociety @PeterMacCC @pros_tic @VanProstateCtr @VCHResearch @UBC @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @Novartis
Clonal hematopoiesis (CH) in the @ANZUPtrials #TheraP study @ASCO #ASCO25 presented by Asli Munzur ■ ¹⁷⁷Lu-PSMA-617: higher incidence of emergent CH compared to cabazitaxel chemotherapy ■ Most new clonal hematopoiesis mutations ¹⁷⁷Lu-PSMA-617 fall in DNA damage repair…
Congrats to our @ANZUPTrials #EVOLUTIONtrial for on their oral presentation by @SandhuShahneen @ASCO25. This Phase 2 #ProstateCancer trial is supported by @PCFA and collaborators @TrialsCentre @bmsnews @Novartis Thanks Study Co-Chair @drlouiseemmett & @CancerAustralia @Prof_IanD
@ANZUPtrials #EVOLUTION trial live at @ASCO #GU25 ¹⁷⁷Lu-PSMA-617 + ipilimumab (n=67) + nivolumab vs. ¹⁷⁷Lu-PSMA-617 (n=33) ■ rPFS favouring ¹⁷⁷Lu immunotherapy: HR 0.53 (95% CI 0.32-0.90) ■ PSA-50 RR 75% vs. 67% ■ Grade 3-4 AEs 76% vs. 29% @SandhuShahneen…
@ANZUPtrials #EVOLUTION trial live at @ASCO #GU25 ¹⁷⁷Lu-PSMA-617 + ipilimumab (n=67) + nivolumab vs. ¹⁷⁷Lu-PSMA-617 (n=33) ■ rPFS favouring ¹⁷⁷Lu immunotherapy: HR 0.53 (95% CI 0.32-0.90) ■ PSA-50 RR 75% vs. 67% ■ Grade 3-4 AEs 76% vs. 29% @SandhuShahneen…
Don't miss the first-in-human VIOLET study being presented #ASCO25 @ASCO Monday June 2 3:00 PM New Frontiers in Prostate-Specific Membrane Antigen Radioligand Therapy (awesome research being presented in this session - don't miss the other talks) In press @TheLancetOncol…
Great to hear the patient perspective at @ASCO #ASCO25 David Matheson ... His initial thought was "cut out all out" but with time to think he opted for radiotherapy...
Pleased to share some first images of Lutetium-177 CA-IX peptide theranostics for metastatic clear cell renal cancer #ASCO25 @ASCO. Ga-68 DPI-4452 PET/CT at baseline and on-treatment shown👇 State-of-the-Science: Novel Diagnostics and Therapeutics in Renal Cell Carcinoma…
Getting ready for @ASCO #ASCO25? ✈️🔬 There’s lots of theranostics … including a dedicated session for prostate cancer. Don’t miss these! 👀
On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the @ANZUPtrials phase II TheraP study, now published in @NatureMedicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across…
Stunning research from @EdmondMKwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative…
New Frontiers in PSMA Radioligand Therapy Is this the "hottest" session at @ASCO #ASCO25 ?? ■ VIOLET: First-in-human trial of Terbium-161 ■ BULLSEYE: Lu-PSMA in oligo-metastatic disease ■ ENZA-p: Biomarkers @pros_tic @PCF_Science
#PRIMARY Score and where it plays a role. @DrMHofman @PeterMacCC. Written coverage by @zklaassen_md @GACancerCenter > bit.ly/3XEDpg5 @PCFnews @PSMAconference #PSMAandBeyond2025
Day 1 of @PSMAconference and Beyond Conference Great panel and Dr. Hoffman talks “virtual biopsies”
@DrMHofman presents at 2025 PSMA & Beyond Conference @UCLA @UCSF @PCFnews ... Impressive attendance! Thanks to organisers: @thomashopemd @CalaisJeremie @CzerninJohannes @urotoday Don't miss our next webinar: Link.prostic.org/webinar